171 related articles for article (PubMed ID: 24962356)
1. Polymalic acid-based nano biopolymers for targeting of multiple tumor markers: an opportunity for personalized medicine?
Ljubimova JY; Ding H; Portilla-Arias J; Patil R; Gangalum PR; Chesnokova A; Inoue S; Rekechenetskiy A; Nassoura T; Black KL; Holler E
J Vis Exp; 2014 Jun; (88):. PubMed ID: 24962356
[TBL] [Abstract][Full Text] [Related]
2. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
Inoue S; Ding H; Portilla-Arias J; Hu J; Konda B; Fujita M; Espinoza A; Suhane S; Riley M; Gates M; Patil R; Penichet ML; Ljubimov AV; Black KL; Holler E; Ljubimova JY
Cancer Res; 2011 Feb; 71(4):1454-64. PubMed ID: 21303974
[TBL] [Abstract][Full Text] [Related]
3. Nanoconjugate based on polymalic acid for tumor targeting.
Ljubimova JY; Fujita M; Khazenzon NM; Lee BS; Wachsmann-Hogiu S; Farkas DL; Black KL; Holler E
Chem Biol Interact; 2008 Jan; 171(2):195-203. PubMed ID: 17376417
[TBL] [Abstract][Full Text] [Related]
4. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
[TBL] [Abstract][Full Text] [Related]
5. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
Inoue S; Patil R; Portilla-Arias J; Ding H; Konda B; Espinoza A; Mongayt D; Markman JL; Elramsisy A; Phillips HW; Black KL; Holler E; Ljubimova JY
PLoS One; 2012; 7(2):e31070. PubMed ID: 22355336
[TBL] [Abstract][Full Text] [Related]
6. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).
Fujita M; Lee BS; Khazenzon NM; Penichet ML; Wawrowsky KA; Patil R; Ding H; Holler E; Black KL; Ljubimova JY
J Control Release; 2007 Oct; 122(3):356-63. PubMed ID: 17630012
[TBL] [Abstract][Full Text] [Related]
7. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
8. Physarum polymalic acid hydrolase: Recombinant expression and enzyme activation.
Mueller W; Haindl M; Holler E
Biochem Biophys Res Commun; 2008 Dec; 377(3):735-40. PubMed ID: 18845127
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight poly(alpha-methyl beta,L-malate) of microbial origin: synthesis and crystallization.
Fernández CE; Mancera M; Holler E; Bou JJ; Galbis JA; Muñoz-Guerra S
Macromol Biosci; 2005 Feb; 5(2):172-6. PubMed ID: 15719432
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
[TBL] [Abstract][Full Text] [Related]
12. Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery.
Lee BS; Fujita M; Khazenzon NM; Wawrowsky KA; Wachsmann-Hogiu S; Farkas DL; Black KL; Ljubimova JY; Holler E
Bioconjug Chem; 2006; 17(2):317-26. PubMed ID: 16536461
[TBL] [Abstract][Full Text] [Related]
13. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.
Spänkuch B; Steinhauser I; Wartlick H; Kurunci-Csacsko E; Strebhardt KI; Langer K
Neoplasia; 2008 Mar; 10(3):223-34. PubMed ID: 18320067
[TBL] [Abstract][Full Text] [Related]
15. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment.
Ljubimova JY; Portilla-Arias J; Patil R; Ding H; Inoue S; Markman JL; Rekechenetskiy A; Konda B; Gangalum PR; Chesnokova A; Ljubimov AV; Black KL; Holler E
J Drug Target; 2013 Dec; 21(10):956-967. PubMed ID: 24032759
[TBL] [Abstract][Full Text] [Related]
17. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
Zazo S; González-Alonso P; Martín-Aparicio E; Chamizo C; Luque M; Sanz-Álvarez M; Mínguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Mol Cancer Ther; 2020 Aug; 19(8):1696-1707. PubMed ID: 32404410
[TBL] [Abstract][Full Text] [Related]
18. Silencing Breast Cancer Genes Using Morpholino Embedded DNA-Tile-AuNPs Nanostructures.
Tunç CU; Öztaş DY; Uzunoğlu D; Bayrak ÖF; Çulha M
Hum Gene Ther; 2019 Dec; 30(12):1547-1558. PubMed ID: 31608694
[TBL] [Abstract][Full Text] [Related]
19. Stage specific expression of poly(malic acid)-affiliated genes in the life cycle of Physarum polycephalum. Spherulin 3b and polymalatase.
Pinchai N; Lee BS; Holler E
FEBS J; 2006 Mar; 273(5):1046-55. PubMed ID: 16478477
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
